CeriBell (CBLL) Projected to Post Quarterly Earnings on Tuesday

CeriBell (NASDAQ:CBLL) is expected to announce its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect the company to announce earnings of ($0.50) per share and revenue of $29.16 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:30 PM ET.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.04). The company had revenue of $28.10 million during the quarter, compared to the consensus estimate of $27.28 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. On average, analysts expect CeriBell to post ($1.96) EPS for the current fiscal year and ($1.62) EPS for the next fiscal year.

CeriBell Stock Down 0.4%

Shares of CBLL stock opened at $27.03 on Tuesday. CeriBell has a 52 week low of $10.85 and a 52 week high of $28.11. The stock has a market cap of $1.04 billion, a P/E ratio of -15.36 and a beta of 0.94. The company’s fifty day simple moving average is $24.70 and its two-hundred day simple moving average is $20.72. The company has a quick ratio of 8.79, a current ratio of 9.18 and a debt-to-equity ratio of 0.16.

Insider Activity

In other news, Director Joseph Taylor sold 13,095 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $23.40, for a total transaction of $306,423.00. Following the sale, the director owned 48,478 shares in the company, valued at $1,134,385.20. The trade was a 21.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CTO Raymond Woo sold 4,887 shares of CeriBell stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $24.33, for a total value of $118,900.71. Following the transaction, the chief technology officer owned 203,118 shares in the company, valued at $4,941,860.94. This represents a 2.35% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 174,905 shares of company stock valued at $4,312,995 over the last quarter. Insiders own 17.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on CBLL. Weiss Ratings raised CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 16th. TD Cowen upped their target price on shares of CeriBell from $29.00 to $33.00 and gave the stock a “buy” rating in a research note on Friday, October 2nd. Raymond James Financial reissued a “strong-buy” rating and set a $29.00 target price on shares of CeriBell in a research report on Thursday, September 3rd. BTIG Research reaffirmed a “buy” rating and set a $30.00 price target on shares of CeriBell in a report on Friday, September 11th. Finally, Barclays raised shares of CeriBell to a “neutral” rating in a report on Tuesday, August 18th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $27.00.

CeriBell Company Profile

CeriBell, Inc is a medical technology company that develops artificial intelligence-enabled neurological diagnostic products. Its technology is designed to help healthcare professionals rapidly identify and monitor seizures, including nonconvulsive seizures that may be difficult to recognize through a standard clinical examination.

The company’s primary product is the Ceribell Rapid Response EEG system, a portable electroencephalography platform that combines a wireless EEG recorder, a simplified disposable headband, and software-based analysis tools.